For fiscal 2025 (ended Dec 31, 2025), Trinity Biotech plc reported $43.78M of revenue and -$37.38M of net income.
TRIB revenue was $43.78M for fiscal 2025 (ended Dec 31, 2025), down 28.9% from fiscal 2024. Compound annual growth was -15.6% over 5 years and -7.9% over 10 years. It rose in 2 of the last 10 fiscal years.
TRIB net income was -$37.38M for fiscal 2025 (ended Dec 31, 2025), compared with -$31.79M in fiscal 2024.
TRIB free cash flow was -$6.02M for fiscal 2025 (ended Dec 31, 2025), compared with -$4.60M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.78M | $61.55M | $56.83M | $62.52M | $81.15M | $101.98M | $90.44M | $97.03M | $99.14M | $99.61M |
| Cost of revenue | $26.90M | $40.11M | $37.38M | $45.25M | $47.70M | $53.40M | $52.31M | $55.59M | $57.25M | $56.13M |
| Gross profit | $16.89M | $21.44M | $19.45M | $17.27M | $33.45M | $48.58M | $38.12M | $41.45M | $41.89M | $43.48M |
| Research and development | $3.63M | $4.54M | $4.38M | $4.14M | $4.50M | $5.08M | $5.33M | $5.37M | $5.66M | $5.04M |
| Selling, general and admin | $24.67M | $28.82M | $31.15M | $26.98M | $22.50M | $26.39M | $27.66M | $29.48M | $32.25M | $30.37M |
| Operating income | -$15.79M | -$21.16M | -$27.05M | -$19.35M | $3.94M | $82.0K | -$24.11M | -$20.23M | -$37.67M | -$39.85M |
| Interest expense | $21.39M | $9.56M | $11.05M | $24.73M | $7.08M | $6.75M | $6.58M | $5.08M | $5.41M | $5.44M |
| Pre-tax income | -$37.18M | -$30.73M | -$36.93M | -$43.78M | -$1.92M | -$6.63M | -$30.00M | -$23.18M | -$39.88M | -$42.14M |
| Income tax | $199.0K | $486.0K | -$59.0K | -$194.0K | -$74.0K | -$620.0K | -$1.01M | -$525.0K | -$1.21M | -$3.56M |
| Net income | -$37.38M | -$31.79M | -$24.02M | -$41.01M | $875.0K | -$6.39M | -$28.91M | -$22.09M | -$40.27M | -$100.63M |
| Diluted shares | 371.5M | 359.2M | 153.1M | 134.9M | 83.6M | 37.7M | 101.9M | 103.5M | 107.5M | 113.2M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.14M | $5.17M | $3.69M | $6.58M | $25.91M | $27.33M | $15.23M | $30.28M | $57.61M | $77.11M |
| Receivables | $11.48M | $16.07M | $13.90M | $15.75M | $16.12M | $22.67M | $20.99M | $24.44M | $20.74M | $22.59M |
| Inventory | $18.83M | $19.37M | $19.93M | $22.50M | $29.12M | $30.22M | $32.02M | $30.36M | $32.80M | $32.59M |
| Current assets | $35.90M | $41.12M | $39.04M | $46.67M | $72.69M | $83.30M | $71.39M | $86.66M | $112.59M | $133.49M |
| Total assets | $105.17M | $103.29M | $59.44M | $92.10M | $118.89M | $130.40M | $131.07M | $151.66M | $192.97M | $249.59M |
| Current liabilities | $141.21M | $32.09M | $15.04M | $17.34M | $100.49M | $27.06M | $19.45M | $17.60M | $21.23M | $25.28M |
| Long-term debt | $210.0K | $210.0K | $210.0K | $210.0K | $83.31M | $82.66M | $82.02M | $81.38M | $92.95M | $92.23M |
| Total debt | $210.0K | $210.0K | $210.0K | $210.0K | $83.31M | $82.66M | $82.02M | $81.38M | $92.95M | $92.23M |
| Total liabilities | $177.15M | $138.47M | $83.38M | $94.28M | $119.21M | $132.62M | $126.36M | $107.61M | $127.78M | $140.87M |
| Shareholders' equity | -$71.98M | -$35.18M | -$23.95M | -$2.18M | -$319.0K | -$2.22M | $4.71M | $44.05M | $65.20M | $108.73M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.93M | -$4.19M | -$11.56M | -$921.0K | $13.24M | $23.75M | $5.42M | $7.23M | $9.25M | $10.23M |
| Capital expenditures | $88.0K | $405.0K | $803.0K | $1.10M | $1.81M | $3.18M | $2.12M | $7.53M | $4.84M | $4.21M |
| Free cash flow | -$6.02M | -$4.60M | -$12.36M | -$2.02M | $11.43M | $20.58M | $3.30M | -$299.0K | $4.41M | $6.01M |
| Investing cash flow | -$6.22M | -$22.97M | $24.76M | -$5.98M | -$8.69M | -$10.20M | -$11.85M | -$17.39M | -$16.18M | -$21.88M |
| Financing cash flow | $12.05M | $28.81M | -$16.04M | -$12.32M | -$6.02M | -$2.72M | -$7.53M | -$16.87M | -$12.64M | -$13.36M |
| Share repurchases | - | - | - | - | - | - | - | $434.0K | $7.80M | $9.32M |
| Stock-based compensation | $324.0K | $1.32M | $2.07M | $1.75M | $1.10M | $792.0K | $758.0K | $1.37M | $928.0K | $1.41M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -28.9% | 8.3% | -9.1% | -23.0% | -20.4% | 12.8% | -6.8% | -2.1% | -0.5% | -0.6% |
| Gross margin | 38.6% | 34.8% | 34.2% | 27.6% | 41.2% | 47.6% | 42.2% | 42.7% | 42.3% | 43.7% |
| Operating margin | -36.1% | -34.4% | -47.6% | -30.9% | 4.9% | 0.1% | -26.7% | -20.8% | -38.0% | -40.0% |
| Net margin | -85.4% | -51.6% | -42.3% | -65.6% | 1.1% | -6.3% | -32.0% | -22.8% | -40.6% | -101.0% |
| Free cash flow margin | -13.7% | -7.5% | -21.7% | -3.2% | 14.1% | 20.2% | 3.6% | -0.3% | 4.4% | 6.0% |
| Return on equity | - | - | - | - | - | - | -613.5% | -50.1% | -61.8% | -92.5% |
| Return on assets | -35.5% | -30.8% | -40.4% | -44.5% | 0.7% | -4.9% | -22.1% | -14.6% | -20.9% | -40.3% |
| Current ratio | 0.25 | 1.28 | 2.60 | 2.69 | 0.72 | 3.08 | 3.67 | 4.92 | 5.30 | 5.28 |
| Debt to equity | - | - | - | - | - | - | 17.40 | 1.85 | 1.43 | 0.85 |
Source: XBRL data Trinity Biotech plc files with the SEC, latest filing dated Apr 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TRIB | $43.78M | -28.9% | -$37.38M | -85.4% | $4.3M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $55.67B |
| ORKA | - | - | -$152.57M | - | $6.92B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.61B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.64B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.45B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.70B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $829.5M |
| ACHV | - | - | -$114.04M | - | $697.7M |